Medifast (MED) Gross Margin (2010 - 2026)

Medifast has reported Gross Margin for 17 years, with the latest figure at 68.06% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 474.0% year-over-year to 68.06%; the trailing twelve-month figure through Mar 2026 stood at 70.12% (down 377.0% YoY), and the FY2025 full-year result was 71.33%, down 247.0% from the prior year.
• Gross Margin for Q1 2026 stood at 68.06%, down from 69.43% in the prior quarter.
• The five-year high for Gross Margin was 75.39% in Q3 2024, with the low at 68.06% in Q1 2026.
• Historically, Gross Margin has averaged 72.0% across 5 years, with a median of 72.45% in 2022.
• Annual changes were most pronounced in 2023 — Gross Margin soared 474 bps — and 2025, when it plunged 587 bps.
• Medifast's Gross Margin stood at 69.27% in 2022, then increased by 7 bps to 74.01% in 2023, then advanced by 0 bps to 74.13% in 2024, then declined by 6 bps to 69.43% in 2025, then slipped by 2 bps to 68.06% in 2026.
• The last three Gross Margin figures came in at 68.06% (Q1 2026), 69.43% (Q4 2025), and 69.52% (Q3 2025), per Business Quant data.